Ionis Pharmaceuticals (IONS) Interest Coverage Ratio (2009 - 2026)
Ionis Pharmaceuticals' quarterly Interest Coverage Ratio came in at 22.76 in Q1 2026, up 36.34% year-on-year from 16.69 in Q1 2025, and up 48.77% quarter-over-quarter from 44.42 in Q4 2025.
Ionis Pharmaceuticals has reported Interest Coverage Ratio for 18 years, with the latest figure at 22.76 in Q1 2026.
- For the quarter ending Q1 2026, Interest Coverage Ratio rose 36.34% year-over-year to 22.76; the trailing twelve-month figure through Mar 2026 stood at 19.23 (up 30.99% YoY), and the FY2025 full-year result was 4.62, up 18.77% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 22.76, up from 44.42 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 33.99 in Q2 2025, with the low at 120.17 in Q4 2022.
- Average Interest Coverage Ratio over 5 years is 34.16, with a median of 35.73 recorded in 2024.
- Year-over-year, Interest Coverage Ratio sank 1868.73% in 2024 and surged 330.89% in 2025.
- Tracing IONS's Interest Coverage Ratio over 5 years: stood at 120.17 in 2022, then surged by 98.88% to 1.34 in 2023, then slumped by 1868.73% to 26.44 in 2024, then plunged by 67.99% to 44.42 in 2025, then surged by 48.77% to 22.76 in 2026.
- The last three Interest Coverage Ratio figures came in at 22.76 (Q1 2026), 44.42 (Q4 2025), and 38.03 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 3.88 |
| 10 | Ionis Pharmaceuticals | 12.61 Bn | 10.69 Bn | 243.11 Mn | -22.76 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.76 |
| Dec 31, 2025 | -44.42 |
| Sep 30, 2025 | -38.03 |
| Jun 30, 2025 | 33.99 |
| Mar 31, 2025 | -35.75 |
| Dec 31, 2024 | -26.44 |
| Sep 30, 2024 | -35.73 |
| Jun 30, 2024 | -14.72 |
| Mar 31, 2024 | -36.02 |
| Dec 31, 2023 | -1.34 |
| Sep 30, 2023 | -34.09 |
| Jun 30, 2023 | -39.37 |
| Mar 31, 2023 | -70.99 |
| Dec 31, 2022 | -120.17 |
| Sep 30, 2022 | -27.65 |
| Jun 30, 2022 | -40.15 |
| Mar 31, 2022 | -27.10 |
| Dec 31, 2021 | 98.57 |
| Sep 30, 2021 | -36.69 |
| Jun 30, 2021 | -30.96 |
| Mar 31, 2021 | -38.10 |
| Dec 31, 2020 | -9.31 |
| Sep 30, 2020 | -15.05 |
| Jun 30, 2020 | -21.20 |
| Mar 31, 2020 | -27.70 |
| Dec 31, 2019 | -11.35 |
| Sep 30, 2019 | 0.21 |
| Jun 30, 2019 | -1.60 |
| Mar 31, 2019 | 10.48 |
| Dec 31, 2018 | 0.94 |
| Sep 30, 2018 | -1.65 |
| Jun 30, 2018 | -4.52 |
| Mar 31, 2018 | -0.30 |
| Dec 31, 2017 | -0.57 |
| Sep 30, 2017 | 1.04 |
| Jun 30, 2017 | 0.55 |
| Mar 31, 2017 | 13.55 |
| Dec 31, 2016 | 1.06 |
| Jun 30, 2016 | -5.08 |
| Dec 31, 2015 | 2.30 |
| Sep 30, 2015 | -5.21 |
| Jun 30, 2015 | 4.89 |
| Mar 31, 2015 | -1.03 |
| Dec 31, 2014 | 1.38 |
| Sep 30, 2014 | -4.30 |
| Jun 30, 2014 | -1.34 |
| Mar 31, 2014 | -6.00 |
| Dec 31, 2013 | -4.07 |
| Sep 30, 2013 | -5.24 |
| Jun 30, 2013 | -1.65 |
| Mar 31, 2013 | 0.34 |
| Dec 31, 2012 | -5.42 |
| Sep 30, 2012 | -4.72 |
| Jun 30, 2012 | 0.71 |
| Mar 31, 2012 | -3.56 |
| Dec 31, 2011 | -3.64 |
| Sep 30, 2011 | -4.68 |
| Jun 30, 2011 | -4.09 |
| Mar 31, 2011 | -4.72 |
| Dec 31, 2010 | -4.67 |
| Sep 30, 2010 | -2.68 |
| Jun 30, 2010 | -5.73 |
| Mar 31, 2010 | -1.51 |
| Dec 31, 2009 | 1.46 |
| Sep 30, 2009 | -3.26 |
| Jun 30, 2009 | -1.53 |